Dr. Faratian and Harrison present a series of articles on the use of Molecular Pathology in personalising therapy for patients with neoplastic and non-neoplastic disease in the upcoming issue. The articles cover genomic, post-genomic, and systems-based approaches to personalised medicine, with a focus on application in the clinic for real cancer patients.

The use of Molecular Pathology in personalising therapy
The use of Molecular Pathology in personalising therapy

 

Dr. Masatoshi Kitagawa edited a special issue on ‘Cell Cycle Control and Cell Fate’ for coming issue of the journal. Here is the brief introduction.

Cell cycle control is important for not only growth and arrest, but also cell fate determination including differentiation, stemness, malignant transformation, senescence and apoptosis. The special issues picks up several processes or pathways regulating “Cell cycle control and cell fate” such as ubiquitin system, signal transduction, chromatin regulation, non-coding RNA, licensing, EMT, senescence, RB- and p53-pathway. I believe that they are attractive as drug targets for not only cancer but also various human diseases.

Cell Cycle Control and Cell Fate
Cell Cycle Control and Cell Fate

 

http://benthamscience.com/cdt/